Mifegymiso is an antihormonal medication consisting of two medications (mifepristone and misoprostol) that work together to block the effects of progesterone for termination of early pregnancy.
Health Canada recently broadened the interpretation of Mifegymiso prescriber to include prescribing health professional, resulting in Nurse Practitioners having the legal authority to prescribe Mifegymiso within Canada. The Saskatchewan Registered Nurses’ Association (SRNA) has determined that it is within the RN(NP)’s scope of practice whom have the appropriate knowledge, skills and competencies to prescribe Mifegymiso to Saskatchewan patients.
Additional resources for RN(NP)s:
- Health Canada updates prescribing and dispensing information for Mifegymiso outlines the expectations for prescribing and dispensing Mifegymiso with key information for health professionals.
- Review the Product Monograph, Patient Medical Information, the Patient Consent Form and the Patient Information card that can be found on the Celopharma website: celopharma.com
- Consider completing the accredited training program through the Society of Obstetricians and Gynecologists of Canada (SOGC); or the online education program through the Celopharma website specific to Mifegymiso inclusive of the Risk Communication